-
ASTRAZENECA LP et al v.BREATH LIMITED et al DC CAFC
- 1:08-cv-01512
- D.N.J.
- Judge: Renee Marie Bumb +1
- Filed: 03/19/2008
- Closed: 04/17/2018
- Latest Docket Entry: 11/05/2019
- PACER
- Docket updated daily
2
Plaintiffs
5
Defendants
1
Accused
Product
2
Patents-in-Suit
3,682
Days in
Litigation
-
ASTRAZENECA LP et al v.BREATH LIMITED et al DC CAFC
- 1:08-cv-01512
- D.N.J.
- Judge: Renee Marie Bumb +1
- Filed: 03/19/2008
- Closed: 04/17/2018
- Latest Docket Entry: 11/05/2019
- PACER
- Docket updated daily
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
17 |
A kit for treating a respiratory disease, the kit comprising (a) a budesonide suspension in a sealed container, the suspension containing 0.05 mg to 15 mg budesonide and a solvent, and (b) a label indicating administration by nebulization in a
view more
|
Invalid
Entry 823 |
18 |
The kit of claim 17, wherein the frequency is once and only once per day.
|
Invalid
Entry 823 |
20 |
The kit of claim 17, wherein the respiratory disease is selected from the group consisting of an inflammatory airway disease, croup, and bronchopulmonary dysplasia.
|
Invalid
Entry 823 |
21 |
The kit of claim 20, wherein the respiratory disease is asthma.
|
Invalid
Entry 823 |
24 |
The kit of claim 17, wherein the patient is one day to fifteen years old.
|
Invalid
Entry 823 |
25 |
The kit of claim 17, wherein the patient is one month to eight years old.
|
Invalid
Entry 823 |
26 |
The kit of claim 17, wherein the patient is six months to five years old.
|
Invalid
Entry 823 |
27 |
The kit of claim 17, wherein budesonide is the sole active ingredient in the composition.
|
Invalid
Entry 823 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of treating a patient suffering from a respiratory disease, the method comprising administering to the patient a nebulized dose of a budesonide composition in a continuing regimen at a frequency of not more than once per day.
|
Invalid (102 and 103)
Entry 823 |
2 |
The method of claim 1, wherein the frequency is once and only once per day.
|
Invalid (102 and 103)
Entry 823 |
3 |
The method of claim 2, wherein budesonide is the only active ingredient in the budesonide composition.
|
Invalid (102 and 103)
Entry 823 |
7 |
The method of claim 6, wherein the respiratory disease is asthma.
|
Invalid (102 and 103)
Entry 823 |
8 |
The method of claim 7, wherein budesonide is the only active ingredient in the budesonide composition.
|
Invalid (102 and 103)
Entry 823 |
9 |
The method of claim 6, wherein the respiratory disease is chronic obstructive pulmonary disease or bronchiolitis.
|
Invalid (102 and 103)
Entry 823 |
12 |
The method of claim 1, wherein the patient is one day to fifteen years old.
|
Invalid (102 and 103)
Entry 823 |
13 |
The method of claim 12, wherein budesonide is the only active ingredient in the budesonide composition.
|
Invalid (102 and 103)
Entry 823 |
14 |
The method of claim 1, wherein the patient is one month to eight years old.
|
Invalid (102 and 103)
Entry 823 |
15 |
The method of claim 14, wherein budesonide is the only active ingredient in the budesonide composition.
|
Invalid (102 and 103)
Entry 823 |
16 |
The method of claim 1, wherein the patient is six months to five years old.
|
Invalid (102 and 103)
Entry 823 |
17 |
The method of claim 16, wherein budesonide is the only active ingredient in the budesonide composition.
|
Invalid (102 and 103)
Entry 823 |
24 |
The method of claim 1, wherein the budesonide composition contains 0.25 mg to 1.0 mg budesonide.
|
Invalid (102 and 103)
Entry 823 |
25 |
The method of claim 24, wherein budesonide is the only active ingredient in the budesonide composition.
|
Invalid (102 and 103)
Entry 823 |
26 |
The method of claim 1, wherein the budesonide composition is a suspension.
|
Invalid (102 and 103)
Entry 823 |
27 |
The method of claim 26, wherein budesonide is the only active ingredient in the budesonide composition.
|
Invalid (102 and 103)
Entry 823 |
28 |
The method of claim 1, wherein budesonide is the only active ingredient in the budesonide composition.
|
Invalid (102 and 103)
Entry 823 |
29 |
A kit for treating respiratory diseases, the kit comprising (a) a budesonide composition in a sealed container, the composition containing 0.05 mg to 15 mg budesonide and a solvent, and (b) a label indicating administration by nebulization in a
view more
|
Invalid
Entry 823 |
30 |
The kit of claim 29, wherein budesonide is the sole active ingredient in the composition.
|
Invalid
Entry 823 |
-
Infringement
Apotex Corporation
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
20-196620255878-202ANDA No. 78-404Generic PULMICORT RESPULE | US 6,598,603 B1 |
6, 11, 18, 21, 22, 23
|
Infringement
Entry 823Entry 716 |
Apotex Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
20-196620255878-202ANDA No. 78-404Generic PULMICORT RESPULE | US 6,598,603 B1 |
6, 11, 18, 21, 22, 23
|
Infringement
Entry 823Entry 716 |
Breath Limited
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
20-196620255878-202ANDA No. 78-404Generic PULMICORT RESPULE | US 6,598,603 B1 |
6, 11, 18, 21, 22, 23
|
Infringement
Entry 823Entry 716 |
Sandoz Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
20-196620255878-202ANDA No. 78-404Generic PULMICORT RESPULE | US 6,598,603 B1 |
6, 11, 18, 21, 22, 23
|
Infringement
Entry 823Entry 716 |
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
20-196620255878-202ANDA No. 78-404Generic PULMICORT RESPULE | US 6,598,603 B1 |
6, 11, 18, 21, 22, 23
|
Infringement
Entry 823Entry 716 |